EvoNext Holdings SA and Ascend Sport Technology AG sign merger agreement

EvoNext Holdings SA / Key word(s): Merger

EvoNext Holdings SA and Ascend Sport Technology AG sign merger agreement

02-Nov-2026 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


This press release or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful or require registration or any other measure and does not constitute an offer of securities for sale in any country.

PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

EvoNext Holdings SA and Ascend Sport Technology sign merger agreement. Share placement of up to CHF 220 million – EvoNext EGM to be held on December 3

  • EvoNext Holdings SA (SIX: EVE) and Ascend Sport Technology AG have signed the merger agreement
  • The transaction will include a share placement of up to CHF 220 million, targeting a free float of approximately 40%, comprising predominantly secondary shares and a smaller primary issuance to support future growth initiatives
  • The Swiss sports technology holding company Ascend will become a publicly listed entity through a merger into EvoNext with its existing listing on SIX Swiss Exchange
  • The company will commence investor pre-marketing (early-look meetings with institutional investors)
  • EvoNext will hold an extraordinary general meeting (EGM) on December 3 to approve the transaction, which remains subject to decisions by the extraordinary general meetings of both companies
  • Following the merger, current shareholders of EvoNext will hold approximately 3.8% of the combined entity
  • The Offering price for share placement is expected to be CHF 2.50 per share
  • Ascend is a Swiss sports technology holding company, bringing together complementary businesses across the sports technology value chain and forming a leading global platform with AI-enabled monetisation capabilities. Ascend serves over 100 rightsholders and more than 500 brands and broadcasters in over 20 countries

Reinach / Lucerne, Switzerland, 2 November 2026 – Following the announcement of a transaction agreement on 12 October 2026 EvoNext Holdings SA (“EvoNext”, SIX: EVE), a Swiss listed holding company, and Ascend Sport Technology AG (“Ascend”), a Swiss sports technology holding company, today announce the signing of the merger agreement. Subject to the approval of both companies’ general meetings, the statutory merger will lead to the formation of a listed Swiss sports technology company to operate under the name of Ascend Sport Technology AG and remain listed on the SIX Swiss Exchange.

 

Merger structure and valuation

Following the statutory merger (merging of Ascend business against issuance of new EvoNext shares) EvoNext will conduct a share placement (the “Offering”) totaling up to CHF 220 million incl. a 10% greenshoe of secondary shares, targeting a free float of approximately 40%. The Offering is expected to consist predominantly of secondary shares to create an attractive free float and establish a diversified institutional shareholder base, complemented by a primary issuance to support Ascend’s continued growth, strategic initiatives and general corporate purposes. The Offering price is expected to be CHF 2.50.

The former Ascend shareholders, members of management and members of the Board of Directors of the combined company, as well as certain EvoNext shareholders will be subject to lock-up arrangements subject to customary exceptions. 50% of the relevant shares will be subject to a 12‑month lock-up period following completion of the transaction, with the remaining 50% subject to a 24‑month lock-up period. Customary orderly market provisions will be in place.

Key figures and strategic guidance

Ascend is a Swiss sports technology holding company. The premium platform for the global sports technology market brings together complementary businesses across the sports technology value chain and forms a leading global platform with AI-enabled monetization capabilities. Ascend’s businesses serve over 100 rightsholders, including sports leagues, clubs and federations such as FIFA and UEFA, as well as more than 500 brands and broadcasters across over 20 countries. They are present in over 12 active top leagues worldwide – including the top five European leagues. 19 of Europe’s top 30 clubs are among their clients and to date over 10,000 matches have been supported by Ascend’s technology.

Ascend generated net revenues of ca. CHF 44 million for the Full Year 25/26 and EBITDA of ca. CHF 25 million – resulting in an attractive EBITDA margin of 57%.[1] The Company’s fiscal year starts on 1 July and ends on 30 June.

The Company’s medium-term target is to increase net revenues by 100% over a four-year period, reflecting the football tournament cycle. Growth will vary across the period due to major international competitions, which materially influence the timing of the revenue. Medium-term growth is supported by multiple structural drivers: increasing share of wallet with existing clients, new customer wins, expansion into new geographies, markets and sports, and continued adoption of its technology. For fiscal year 26/27 Ascend expects net revenue growth of ca. 10%, as the year marks the beginning of a new cycle with less revenue from international competitions.

In terms of profitability and over the medium term, the company aims for an EBITDA margin of ca. 50% driven by scale and an increasing contribution from higher margin Digital Overlay and marketplace revenues. For fiscal year 26/27 the Company expects EBITDA in line with 25/26 as a result of additional functions and costs required for a listed company.

The Company is headquartered in Lucerne and expects a stable tax rate going forward.

Net working capital in % of net revenues is expected to gradually decrease to ca. 30% in the medium-term from an expected range of 30-35% for fiscal year 26/27. In 25/26 the ratio was ca. 35%. The company expects capital expenditures in % of net revenues to gradually trend towards the mid-teens from an expected range of 20-24% in 26/27 after ca. 27% in 25/26. This reflects the lower capital intensity as the business scales, with absolute capex broadly in line with historical levels while leveraging hardware investments already made.

Currently, there is no dividend payout foreseen. The cash generated will be used to support organic growth, selective rights acquisition and a disciplined M&A strategy, focused on increasing market share as well as geographic and capability driven add-on acquisitions.

Extraordinary General Meeting of EvoNext and of Ascend will be held on 3 December 2026

The resolutions on the Merger will become effective only once shareholders of both companies have approved the merger agreement.

EvoNext Holdings SA will publish the invitation to the Extraordinary General Meeting (EGM) at the latest on 12 November 2026 in the Swiss Official Gazette of Commerce (SOGC) and also on the EvoNext Website. The EGM will be held on Thursday, 3 December 2026, at 10.00 a.m. CET in Zurich.

The Board of Directors of EvoNext unanimously recommends that shareholders approve the transaction. EvoNext will inform shareholders and the market of any material new developments in due course.

The Extraordinary General Meeting of Ascend is also expected to resolve on the approval of the merger agreement and the Merger on 3 December 2026.

Documentation relating to the merger, including the merger report, shareholder information and invites to the extraordinary general meetings is available to shareholders in accordance with applicable legal and regulatory requirements as announced today in the SOGC.

Contact for investors and media

EvoNext Holdings SA

investors@evonextholdings.com

susanne.muehlemann@lemongrass.agency / +41 79 223 70 81

Disclaimer

This publication constitutes neither an offer to sell nor a solicitation to buy securities of EvoNext Holdings SA and it does not constitute a prospectus or a similar notice within the meaning of articles 35 et seqq. or 69 of the Swiss Financial Services Act. Any offer and listing of any securities in EvoNext Holdings SA (“Securities”) will be made solely by means of, and on the basis of, a prospectus which is to be published. An investment decision regarding any publicly offered Securities should only be made on the basis of such prospectus. The prospectus will be available free of charge from the accompanying bank.

This publication may contain specific forward-looking statements, e.g., statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of EvoNext Holdings SA or Ascend Sport Technology AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. EvoNext Holdings SA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. Moreover, financial information contained in this publication may be preliminary and unaudited.

This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as “Relevant Persons”). Any potential investment or investment activity to which this communication relates will be available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.

This communication does not constitute an “offer of securities to the public” within the meaning of Regulation 2017/1129 of the European Union (the “Prospectus Regulation”) of the securities referred to in it (the “Securities”) in any member state of the European Economic Area (the “EEA”) or, in the United Kingdom (“UK”), the UK Public Offers and Admissions to Trading Regulations 2024 (the “POATRs”). Any placements of any Securities to persons in the EEA or the UK will be made pursuant to an exemption under the Prospectus Regulation or the POATRs (as applicable), as implemented in member states of the EEA or the UK, from the requirement to produce a prospectus for offers of Securities.

Any securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to US persons (as such term is defined in Regulation S under the Securities Act) unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The issuer of the securities has not registered, and does not intend to register, any portion of any potential placements in the United States, and does not intend to conduct a public offer of securities in the United States.

This communication is not for distribution in the United States, Canada, Australia, Japan or any other jurisdiction into which the same would be unlawful and does not constitute an offer of securities for sale in such countries. This communication does not constitute an offer to sell, or the solicitation of an offer to buy, securities in any jurisdiction in which it is unlawful to do so.

 

 

 

 

 

 

 

 

[1] 2025/2026 audit not yet completed

Additional features:

File: 2026_11_02_EvoNext Ad hoc Release_Merger Agreement_EGM


End of Inside Information


Language: English
Company: EvoNext Holdings SA
Angensteinerstrasse 6
4153 Reinach
Switzerland
Phone: +41 61 485 20 00
E-mail: investors@evonextholdings.com
Internet: www.evonextholdings.com
ISIN: CH1262055788
Valor: 126205578
Listed: SIX Swiss Exchange
EQS News ID: 2426066

 
End of Announcement EQS News Service

2426066  02-Nov-2026 CET/CEST

SKAN Group AG informs about the proceedings by the Office of the Attorney General of Switzerland from 2023

SKAN AG

/ Key word(s): Miscellaneous

SKAN Group AG informs about the proceedings by the Office of the Attorney General of Switzerland from 2023

02.11.2026 / 07:00 CET/CEST


Media Information

SKAN Group AG informs about the proceedings by the Office of the Attorney General of Switzerland from 2023

Allschwil, 2 November 2026 – On 25 and 26 May 2023, SKAN Group AG announced in ad hoc releases that the Office of the Attorney General had launched an insider trading investigation against the then-Chairman of the Board of Directors and two employees. The proceedings against the former Chairman of the Board of Directors have since been dismissed. The Office of the Attorney General of Switzerland has dropped all allegations, with the state bearing the full cost of the proceedings.

The ongoing proceedings involve the CFO and the Head of the Services, Digital & Single-Use Systems segment. The trial on the charges brought by the Office of the Attorney General of Switzerland will take place on 5 November 2026 at the Federal Criminal Court, with the first-instance decision to be announced on 17 November 2026.

At the time the investigation was launched in 2023, the Board of Directors conducted a thorough assessment of the situation and expressed its confidence in both persons. This assessment remains valid. The Board of Directors upholds the presumption of innocence and is maintaining both persons in their functions.

SKAN Group AG has the greatest interest in the ongoing proceedings being concluded as quickly as possible and is cooperating closely with the authorities. As soon as the first-instance decision has been announced, SKAN Group AG will inform again.

Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13

Financial calendar:

28 January 2027 Publication of preliminary key figures for the 2026 financial year
23 March 2027 Publication Annual Results 2026
28 April 2027 Annual General Meeting 2027

 

SKAN – together always one step ahead

SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, software, services and single-use systems. Innovative solutions and a customer-focused life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs around 1700 people. About half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, France, Slovenia, Croatia, Japan, the USA and Brazil.


End of Media Release


Language: English
Company: SKAN AG
Kreuzstrasse 5
4123 Allschwil
Switzerland
Phone: +41 43 268 32 32
E-mail: info@skan.com
ISIN: CH0013396012
Valor: 1339601
Listed: SIX Swiss Exchange
EQS News ID: 2426062

 
End of News EQS News Service

2426062  02.11.2026 CET/CEST

Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline

Fresenius SE & Co. KGaA

/ Key word(s): Agreement

Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline (news with additional features)

02.11.2026 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


  •  Exclusive option rights for up to 37 potential first-to-market biosimilar candidates to significantly expand Fresenius’ portfolio from 29 marketed and pipeline molecules today to up to 66 in the next decade, addressing more than €370 billion in originator sales; the largest development agreement announced in the biosimilars industry to date.  
  • Agreement gives Fresenius full strategic flexibility to select and advance biosimilar candidates to develop, against its established selection criteria, while retaining full commercialization economics of products under the agreement.  

  • Fresenius will determine the long-term manufacturing strategy for each candidate, with optionality to leverage the mAbxience network, wholly owned since October 2026. 

  • The next-generation portfolio spans 13 therapeutic areas and multiple biologic technologies, including monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins.  

Fresenius SE & Co. KGaA (XETR: FRE; OTCM: FSNUY) today announced that it has entered an exclusive development agreement with WuXi Biologics (2269.HK), a leading global contract organization for research, development and manufacturing. WuXi Biologics brings proven large-scale biologics development and manufacturing capability, a track record across monoclonal and bispecific antibodies and antibody-drug conjugates, and a worldwide network spanning Europe, the United States, China and Singapore. The agreement significantly expands and accelerates Fresenius’ biosimilars pipeline while preserving strategic flexibility and disciplined capital allocation. It provides access to a scalable pathway to increase the portfolio from 29 marketed and pipeline molecules today to up to 66 molecules, addressing more than €370 billion in originator list-price-based-sales, extending Biopharma growth in the long term beyond its 2030 ambition. 

The agreement provides Fresenius with exclusive access to up to 37 identified biosimilar candidates over the next decade, making it the largest development agreement announced in the biosimilars industry to date. Development programs will be selected and advanced against Fresenius’ established selection criteria, based on market attractiveness, development risk, and expected returns. Fresenius will hold exclusive global commercialization rights, including marketing authorizations, and the full economics of each commercialized product under the agreement.  

Michael Sen, Chief Executive Officer of Fresenius, said: “We are doubling down on our Biopharma business. With this agreement we are gaining access to development capabilities in a market where speed and scale are of the essence. It provides a disciplined, scalable way to potentially triple our portfolio while retaining economic ownership, strategic control and the flexibility to allocate capital to the most compelling opportunities. Combined with the full ownership of mAbxience, this fuels our Biopharma growth well beyond 2030.” 

The next-generation portfolio is expected to span 13 therapeutic areas, including expanding into neurology, nephrology and cardiopulmonary, while further strengthening Fresenius’ established positions in oncology, immunology, and gastroenterology. It will encompass multiple biologic technologies, including monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. Initial development is expected to focus on polatuzumab vedotin, an antibody-drug conjugate for the treatment of diffuse large B-cell lymphoma, and teprotumumab, a monoclonal antibody for the treatment of thyroid eye disease. 

The agreement forms part of a balanced pipeline expansion strategy through internal R&D, targeted collaboration, and selective in-licensing. It gives Fresenius privileged access to the rapidly advancing biotech landscape worldwide and combines this with Fresenius’ global manufacturing and commercialization network. Development activities are expected to be conducted using WuXi Biologics’ global network. Building on the recent acquisition of Spain-headquartered mAbxience, the agreement significantly expands the funnel of potential development candidates for Fresenius’ wholly owned platform, enabling greater value capture across the development, manufacturing and commercialization value chain.  

Financial Considerations 

Fresenius’ full-year 2026 guidance remains unchanged, and the company confirms the 2030 Biopharma ambition announced in December 2025 of – approximately doubling Biopharma revenue compared with 2025 at an EBIT margin of around 20% – which relates to the existing marketed and late-stage portfolio. The agreement is additive, expanding the opportunity beyond 2030, and, as a result, Fresenius expects to raise its long-term Biopharma ambitions significantly.  

Under the terms of the agreement, Fresenius will compensate WuXi Biologics on a fee-for-service basis for each biosimilar candidate that Fresenius selects for development. Research and development investment scales only as selected programs progress, with each option exercised against Fresenius’ established selection criteria (market attractiveness, development risk, and expected returns). Fresenius will determine the long-term manufacturing strategy for each biosimilar candidate, including the potential progressive transfer of selected products to mAbxience. Fresenius will hold exclusive global commercialization rights, including marketing authorizations, and the full economics of each commercialized product under the agreement. 

As selected candidates advance, Biopharma research and development expenditure and profitability will correspondingly reflect the increased level of investment during the development phase, ahead of future revenue and profitability growth.  

The agreement fits within Fresenius’ unchanged financial framework, with continued priority on a strong balance sheet and further deleveraging; it is funded from operating cash flow and requires no new financing. Fresenius is rated BBB with a positive outlook by S&P, Baa3 with a stable outlook by Moody’s, and BBB- with a positive outlook by Fitch. 

# # # 

Related Publications 

The 1 October 2026 announcement of Fresenius’ acquisition of the remaining 45% of mAbxience is available here. The 31 March 2022 announcement of Fresenius Kabi’s acquisition of a 55% majority stake in mAbxience is available here, and the 1 August 2022 completion announcement here. The Biopharma ‘Meet the Management’ presentation of 15 December 2025 is available here. 

About polatuzumab vedotin  

Polatuzumab vedotin is an antibody-drug conjugate (ADC) marketed under the brand name Polivy® for the treatment large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma.1  

Globally, DLBCL accounts for approximately one-third of non-Hodgkin lymphomas.² In 2024, more than 562,000 new cases of non-Hodgkin lymphoma were diagnosed worldwide, with approximately 235,000 deaths attributed to the disease.3  

The polatuzumab vedotin ADC comprises a monoclonal antibody directed against CD79b, a protein expressed on B cells including DLBCL cells, linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE) through a cleavable linker. Following binding to CD79b, the ADC is internalized and MMAE is released, disrupting microtubules and leading to cell death.1 

Polivy® is administered by intravenous infusion and is a registered trademark of Genentech, Inc. 

About teprotumumab 

Teprotumumab is a human monoclonal antibody marketed under the brand name Tepezza® for the treatment of thyroid eye disease (TED), a rare autoimmune condition associated with Graves’ disease.4 TED is estimated to affect approximately 16 women and 3 men per 100,000 people annually, with around 25-50% of patients with Graves’ disease developing signs and symptoms of TED.5 

Teprotumumab binds to and inhibits the insulin-like growth factor-1 receptor (IGF-1R), a receptor involved in cellular signaling pathways associated with the development and progression of TED. By inhibiting IGF-1R signaling, teprotumumab helps reduce the inflammatory and tissue-remodeling processes associated with the disease. Tepezza® is administered by intravenous infusion and is a registered trademark of Amgen Inc. 

 

About Fresenius 

Fresenius (XETR: FRE, OTCM: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, medical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450million peopleeach year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27million patientsannually. 

With more than178,000employees and operating in more than 60 countries, Fresenius generated €22.6billion in revenue in 2025.  

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.  

Press Contact:
Steffi Kim
Group Communications
Fresenius SE & Co. KGaA 
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
M +49 175 3284 722
steffi.kim@fresenius.com

 

References 

[1] Polivy® (polatuzumab vedotin-piiq) U.S. Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761121s008lbl.pdf [Last accessed October 2026]. 

[2] Wang, S. S. (2023) Epidemiology and Etiology of Diffuse Large B-Cell Lymphoma (DLBCL). Semin. Hematol. 60, 255–266.  

[3] International Agency for Research on Cancer. Global Cancer Observatory: Non-Hodgkin Lymphoma Fact Sheet, GLOBOCAN 2024. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf [Last accessed October 2026] 

[4] Tepezza® (teprotumumab-trbw) U.S. Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761143s012lbl.pdf [Last accessed October 2026]. 

[5] Moledina, M., Damato, E. M. & Lee, V. (2024) The changing landscape of thyroid eye disease: current clinical advances and future outlook. Eye 38, 1425-37. 

Cautionary Statement on Forward-Looking Statements 

This release contains forward-looking statements that are subject to various risks and uncertainties including statements regarding the potential number of biosimilar candidates developed under the agreement with WuXi Biologics, the resulting pipeline size (including references to “up to 66” molecules), the timing and scope of any transfer of manufacturing to the mAbxience network, and Fresenius’ growth prospects beyond 2030. Whether, when and how many candidates are developed under the agreement remains subject to Fresenius’ future exercise of options on a candidate-by-candidate basis, and no assurance can be given that any, or all, of the identified candidates will be developed or will reach the market. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release. 

Fresenius SE & Co. KGaA 
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852 
Chairman of the Supervisory Board: Wolfgang Kirsch 

General Partner: Fresenius Management SE 
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673 
Management Board: Michael Sen (Chairman), Sara Hennicken, Dr. Marc-Alexander Mahl,  
Dr. Michael Moser, Dr. Christian Pawlu   
Chairman of the Supervisory Board: Wolfgang Kirsch 


Additional features:

File: 20261102_FSE_PressRelease_Biopharma_Development_Agreement
File: Image_1_Fresenius_Headquarter
File: Image_2_mAb_binding_to_target


02.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-97033
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE000FRE5EN2
WKN: FRE5EN
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Hamburg, Hanover, Stuttgart, Tradegate BSX; Luxembourg Stock Exchange
LEI Code: XDFJ0CYCOO1FXRFTQS51
EQS News ID: 2426078

 
End of News EQS News Service

2426078  02.11.2026 CET/CEST

GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging

GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging




GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging

  • Extra-wide-bore, cable-less ceiling gantry and real-time digital twin aim to keep cases moving, regardless of procedure type or patient size
  • AI-powered precision imaging designed to automatically balance image quality and radiation dose in real time across 2D and 3D imaging
  • Designed to work with the GE HealthCare clinical applications and compatible third-party technologies care teams already rely on, with the flexibility to support future solutions
  • Predictive service support through OnWatch Predict, a deep learning-based technology designed to help minimize clinical operations disruptions for a reliable patient schedule

CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) today introduced Allia™ Celeo,* a ceiling-mounted image guiding system, at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in San Diego. Developed around the principle of smooth procedural flow and built for interventional suites that prioritize high patient throughput and versatility across many indications, Allia Celeo pairs an extra-wide-bore C-arm with intuitive user interface, an AI-powered image chain, and compatibility with OnWatch™ Predict remote monitoring with the goal of helping cardiology and interventional radiology teams move through each stage of a procedure with greater confidence and without losing momentum.


“Every interventional suite has its own rhythm, and care teams need a system that adapts to the way they work rather than the other way around,” said Jyoti Gera, Chief Executive Officer, CardioVascular and Interventional Solutions (CVIS), Advanced Imaging Solutions (AIS), GE HealthCare. “Allia Celeo extends our Allia platform with a ceiling-mounted system built for that kind of flexibility, giving hospitals more choice in how they configure their interventional suites while supporting our vision for more personalized, precise care.”

Allia Celeo’s slim, symmetrical ceiling gantry uses integrated cabling, providing space around the system for staff and equipment. Its extra-wide bore is designed to let the C-arm rotate freely around the patient and reach steep angulations, even for patients with a high body mass index (BMI). A slim C-arm and thin detector lift aim to limit visual obstruction so team members can see and communicate with one another across the table. Fast ceiling panning and extended table coverage support imaging from head to toe, while InnovaBreeze uses automatic table and gantry movements to support assessment of the full lower-limb anatomy in a single acquisition.

To help maintain procedural momentum, clinicians can adjust gantry and table positions from multiple locations, while an on-screen digital twin is designed to help optimize positioning. Personalized controls and layouts are designed to let clinicians tailor the system to their workflow.

The core of Allia Celeo is built on an image chain for the platform that includes AI-enabled features designed to support confident decision-making across patient anatomies and clinical complexities. It is designed to automatically adjust acquisition parameters with the goal of delivering consistent image quality at the lowest dose, and the advanced image rendering provides one-click access to highly differentiated cardiac image renderings designed to match each operator’s preference.

“We designed Allia Celeo around a simple idea: a procedure should move at the pace of the care team, not the equipment,” said Kat Davis, General Manager, Interventional Solutions, CVIS, AIS, GE HealthCare. “From a digital twin that previews gantry positioning to an image chain that manages dose in the background, each element is intended to reduce the small interruptions that add up over a day in the interventional suite, so clinicians can stay focused on their patients.”

Allia Celeo is designed to be compatible with cleared GE HealthCare solutions that support coronary and structural heart procedures, including StentViz and 3DStenti for stent visualization, Valve ASSIST 2 for structural heart planning, and the cleared Mac-Lab hemodynamic system with integrated FFR and dPR indexes. For interventional radiology and oncology, compatible tools such as Embo ASSIST AI, Vessel ASSIST and Needle ASSIST are designed to support embolization planning, 3D roadmapping and needle guidance. The system also supports integration with Vscan Air™ handheld ultrasound and compatible third-party intravascular imaging and physiology systems and is built with the flexibility to support future solutions.ii

Beyond the procedure itself, Allia Celeo is designed to be compatible with OnWatch Predict, a GE HealthCare technology that combines 24/7 remote monitoring with deep learning-based predictive analytics to anticipate unplanned downtime and support proactive service planning, with the goal of minimizing disruptions to clinical operations and supporting more predictable patient schedules.

Allia Celeo is the second new system in the Allia family to be introduced in less than a year, following the floor-mounted Allia Moveo, unveiled in 2025 and commercially launched earlier this year, alongside an upgrade program that brings the latest Allia platform advancements to existing customers. Together, these additions reflect GE HealthCare’s ongoing evolution of the Allia family to address different clinical challenges in the interventional suite, with an AI-enabled portfolio designed to deliver patient access and precision imaging across a wide range of room configurations and procedure types.

To see the system in person, visit GE HealthCare at booth #5237 at TCT 2026, or contact your GE HealthCare sales representative for more information.

* Allia Celeo is CE marked. It is 510(k) pending with the U.S. FDA, is not available for sale in the United States, and may not be available in all regions.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.

___________________________ 

i 3DStent available with 30-cm detector.

ii Applications sold separately. May not be available in all markets.

 

Contacts

GE HealthCare Media Contact:
Eric Tatro

M +1 312 459 6140

eric.tatro@gehealthcare.com

Reflow Medical Reports One-Year Results from DEEPER CORONARY Study of Investigational Coronary Spur® Elute Sirolimus-Eluting Retrievable Stent System

Reflow Medical Reports One-Year Results from DEEPER CORONARY Study of Investigational Coronary Spur® Elute Sirolimus-Eluting Retrievable Stent System




Reflow Medical Reports One-Year Results from DEEPER CORONARY Study of Investigational Coronary Spur® Elute Sirolimus-Eluting Retrievable Stent System

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–#TCT2026–Reflow Medical, Inc., a leading developer of innovative devices for treating complex cardiovascular disease, announces the presentation of one-year clinical results from the first-in-human DEEPER CORONARY study at Transcatheter Cardiovascular Therapeutics (TCT) 2026, the annual scientific symposium of the Cardiovascular Research Foundation (CRF), in San Diego. The study evaluates the investigational coronary Spur® Elute Sirolimus-Eluting Retrievable Stent System for coronary in-stent restenosis (ISR).




The results were presented by Kathleen Kearney, MD, FSCAI of Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, on behalf of Scott Harding, MD, Director of the Cardiology Research Group at Wellington Hospital, Wellington, New Zealand, the study’s principal investigator.

DEEPER CORONARY is a single-center, first-in-human pilot study designed to evaluate the short-term safety of the investigational coronary Spur Elute Stent System as a primary treatment for coronary ISR. All nine treated subjects completed 12-month follow-up. Freedom from major adverse cardiac events (MACE) and from all-cause mortality was 100% at one year, and no unanticipated adverse device effects or device-related serious adverse events were reported. All patients showed improvement in Canadian Cardiovascular Society (CCS) angina class, with a median improvement of three classes.

Device delivery and lesion success, defined as less than 30% residual stenosis, were achieved in all nine patients. Mean residual stenosis was 13.3% and mean acute lumen gain was 1.8 mm after treatment with the coronary Spur Elute.

“Coronary ISR remains a significant clinical challenge, particularly in patients with multiple stent layers. The absence of major adverse cardiac events at one year in this first-in-human study is encouraging and supports further evaluation of a treatment approach that combines temporary scaffolding with sirolimus delivery, without leaving another permanent implant behind,” said Dr. Kearney.

“Completing 1-year follow-up in all nine patients is an important milestone,” said Dr. Harding. “While this is a small first-in-human study, the clinical outcomes are reassuring and provide a strong rationale for further investigation of this technology in patients with coronary ISR.”

The coronary Spur Elute is designed to create microchannels that facilitate drug delivery into the vessel wall, complemented by direct contact sirolimus transfer from the drug-coated scaffold struts and integrated balloon. The temporary scaffold supports the vessel and permits coronary perfusion while the balloon is deflated. Together, these mechanisms are designed to optimize/maximize luminal expansion, enhance drug delivery, and reduce the risk of recurrent restenosis. Following treatment, the system is fully retrieved, leaving no additional metallic implant behind.

“We aim to change how restenosis is treated by combining mechanical vessel support with targeted drug delivery, without leaving additional metal behind,” said Isa Rizk, CEO and Co-Founder of Reflow Medical. “These 1-year results represent an important step in advancing the coronary Spur platform and reinforce our commitment to developing differentiated solutions for complex coronary disease.”

The coronary Spur Elute Sirolimus-Eluting Retrievable Stent System is an investigational device only.

About Reflow Medical, Inc.

Reflow Medical is a global company that partners with leading physicians to develop innovative technologies addressing unmet clinical needs in the endovascular treatment of complex cardiovascular disease. The company’s portfolio includes coronary and peripheral microcatheters, crossing catheters, and its proprietary Retrievable Scaffold Therapy (RST) platform. The coronary Cora Catheters line is FDA cleared. The peripheral product line includes Wingman™, Spex®, and Spex LP®, which have FDA clearance and CE mark, and Spur®, which has received FDA De Novo authorization and CE mark. Reflow Medical is headquartered in San Clemente, California.

Contacts

Rebekah Meola

rmeola@reflowmedical.com
(949) 481-0399 Ext. 9

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results




Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

Analyses presented at TCT highlight how patient selection, timely Impella support and consistent care protocols may help improve outcomes during and after complex heart procedures


SAN DIEGO–(BUSINESS WIRE)–#PressRelease–Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symposium (TCT 2026) that report positive survival and patient outcomes data when Impella™ heart pumps are used to support a patient’s heart during and after high-risk percutaneous coronary intervention (HRPCI). Real-world and observational registry data from 1,379 HRPCI patients across hospitals in the U.S. and Europe show lower in-hospital cardiovascular mortality and lower 30- and 90-day mortality rates than those recently reported in CHIP-BCIS3. These contemporary findings from real-world U.S. and European experience with Impella-supported HRPCI provide important clinical context in contrast to the CHIP-BCIS3 study results.

“Data from these high-impact presentations add to more than two decades of evidence supporting Impella use in complex HRPCI patients,” said Navin Kapur, M.D., chief medical and scientific officer, Heart Recovery, MedTech, Johnson & Johnson. “They also reinforce that outcomes depend not only on the device but how and when it is used, from selecting the right patients and procedural approach to post-procedural management and critical care.”

The following data will be presented during TCT:

  • TCT 197: Protected PCI with Microaxial-Flow Pump Support: Real-World Evidence from the TRI-GUARD-PCI Registry (Matthias Bossard, M.D., 11/1/26; 11 a.m. PST, station 4). This multicenter analysis of 279 patients undergoing elective protected PCI with Impella at hospitals in Germany, Switzerland and Austria showed lower 30-day (6.1%) and 180-day (7.9%) all-cause mortality rates than previously reported in the CHIP-BCIS3 trial Kaplan-Meier curve.

“These real-world results provide important insights into outcomes following Impella-supported high-risk PCI in contemporary clinical practice,” said Matthias Bossard, M.D.1, an interventional cardiologist and researcher now at Dalhousie University in Halifax, Nova Scotia, who conducted this research while at the Heart Center at Luzerner Kantonsspital in Lucerne, Switzerland, in collaboration with Mohamed Ayoub, MD, from Germany. “The findings may help inform patient selection and procedural planning for complex high-risk interventions.”

  • TCT 888: Peri-procedural and Early Post-Procedural Cardiovascular Mortality Following HRPCI (Vasileios Panoulas, M.D., 11/2/26, 1 p.m. PST, station 2). Using a multicenter U.S. registry, this analysis of 522 patients who underwent Impella-supported HRPCI showed cardiovascular mortality of 3.4% at time of discharge compared with approximately 8% in the CHIP-BCIS3 study for patients treated with Impella on day 4 post-randomization. Kaplan-Meier curve estimates of cardiovascular mortality were 4.7% at 30 days and 6.5% at 90 days—both numerically lower than the corresponding rates reported in CHIP-BCIS3.

“This analysis provides real-world perspective on the use of Impella during HRPCI and highlights differences from the CHIP-BCIS3 study protocol,” said Vasileios Panoulas, M.D.,2 physician at Royal Brompton and Harefield Hospitals in London and the abstract’s lead author. In the CHIP-BCIS3 treatment arm, the device was removed before patients left the catheterization lab whereas in the LOQI study, one in six patients were supported by Impella for more than three hours. “These observations suggest a potential relationship between duration of support, post-procedural management and patient outcomes,” adds Panoulas.

  • TCT 1228: Clinical Characteristics and Early Mortality in a High-Risk PCI Cohort Similar to CHIP-BCIS3 Undergoing Impella Support: Insights from PROTECT III (Vasileios Panoulas, M.D., 11/3/26, 8:50 a.m. PST, station 10). This analysis identified patients enrolled in the PROTECT III study who would meet the study entry criteria for the CHIP-BCIS3 trial. The in-hospital all-cause mortality for those 578 Impella-supported patients was 4.7%, which is lower than the estimated ~8% mortality reported in CHIP-BCIS3.

“In the high-risk PROTECT III cohort, Impella-supported HRPCI was performed in patients with severe left ventricular dysfunction and complex coronary anatomy, including frequent left main and multivessel treatment, with lower mortality rates than reported in CHIP-BCIS3,” said Panoulas3, who is presenting this data at TCT. “Understanding mortality after HRPCI requires looking at patient risk at baseline, procedural complexity and the importance of post-procedure patient management.”

Johnson & Johnson MedTech continues to study Impella across a range of coronary heart conditions, including the PROTECT IV randomized controlled trial, with results anticipated in 2027. This trial design builds on data demonstrating survival and patient outcomes and helps care teams further refine best practices for people with complex heart disease who need percutaneous coronary intervention. To learn more about PROTECT IV and our ongoing clinical research trials, visit https://www.heartrecovery.com/en-us/education/ongoing-studies/protect-iv.

About Impella Heart Pumps

Impella heart pumps are temporary mechanical circulatory support devices designed to unload the heart and provide hemodynamic support. Impella technology is used in appropriately selected patients with severe coronary artery disease or cardiogenic shock, consistent with applicable indications and labeling. Impella has been used to treat more than 450,000 patients globally.

Cardiovascular Solutions from Johnson & Johnson MedTech

Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary and peripheral artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more information about heart recovery, visit https://www.heartrecovery.com/en-us.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in surgery, orthopaedics, vision, and cardiovascular solutions at https://www.jnjmedtech.com/. Follow us at @jjmt_heartrecov and on LinkedIn.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to Impella heart pumps and the company’s research and innovation programs. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges inherent in research and development; uncertainty of clinical success and regulatory approvals; commercial success; manufacturing difficulties and delays; competition; intellectual property challenges; product efficacy or safety concerns; regulatory actions; changes in customer behavior and spending; changes in laws and regulations; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

____________________

1 Dr. Bossard is a paid consultant for J&J MedTech and was not compensated for his quote in this press release.

2 Dr. Panoulas is a paid consultant for J&J MedTech and was not compensated for his quote in this press release.

3 Dr. Panoulas is a paid consultant for J&J MedTech and was not compensated for his quote in this press release.

 

Contacts

Media contacts:

Jenny Leary
jleary1@its.jnj.com

Heather Breslau
hbreslau@its.jnj.com

STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE

STRATEC SE / Key word(s): Mergers and Acquisitions / Sale of Business Units

STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE

30-Oct-2026 / 22:49 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE

Birkenfeld, October 30, 2026

STRATEC SE, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard), today signed an agreement with a consortium of Indian investors for the sale of its subsidiary Diatron MI. The sale comprises all Diatron products in the fields of hematology and clinical chemistry. Diatron’s OEM business in molecular and immunodiagnostics was carved out prior to the sale and remains part of the STRATEC Group. The fixed purchase price amounts to € 10.0 million. In addition, earn-out payments have been agreed. Closing of the transaction is expected in the fourth quarter of 2026.

Based on current planning for the 2026 financial year, the sold business is expected to generate sales of around € 20.0 million and adjusted EBIT of around minus € 10.0 million. Due to the implementation of measures relating to the sale, STRATEC will recognize non-cash impairments of € 44.1 million in the third quarter of 2026. Furthermore, the sale is expected to result in a negative non-cash deconsolidation effect of between € 4.0 million and € 9.0 million in the fourth quarter of 2026.

The sales and earnings contributions from the divested business, as well as the impairments arising in connection with the transaction and the deconsolidation effect, will be retrospectively allocated to discontinued operations for the 2026 financial year. To account for the sale of this loss-bringing business and the company’s updated planning, the Board of Management is amending its guidance for the 2026 financial year as follows: Based on pro-forma sales (adjusted to exclude the sold business) of € 223.5 million for the 2025 financial year, STRATEC expects to generate stable to slightly higher sales on a constant-currency basis in the 2026 financial year. Following separation of the sold business from continuing operations, STRATEC is forecasting an adjusted EBIT margin of between 13.0% and 15.0% for the 2026 financial year (previously: around 10.0% prior to the separation). The sale also has implications for STRATEC’s medium-term targets as communicated at the beginning of the year. These are therefore no longer being upheld and will be updated at the latest upon publication of the 2026 Annual Report.

The quarterly statement for the first nine months of 2026 will be published on November 12, 2026. Based on the information available, STRATEC expects to report sales of € 164.9 million and an adjusted EBIT margin of 8.3% for the first nine months of 2026. Both key figures still include sales and operating earnings contributions from the sold business. The aforementioned earnings figures have been adjusted to exclude amortization arising from acquisitions-related purchase price allocations and other non-recurring items, including the impairments recognized.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler, CFA | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
ir@stratec.com
www.stratec.com

End of Inside Information


30-Oct-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 529900ZZJWANAFSPGV30
EQS News ID: 2425848

 
End of Announcement EQS News Service

2425848  30-Oct-2026 CET/CEST

Avenzo Therapeutics to Present Preliminary Phase 1 Results from ORION-1 Study of AVZO-023, a Selective CDK4 Inhibitor, at the 2026 San Antonio Breast Cancer Symposium

Avenzo Therapeutics to Present Preliminary Phase 1 Results from ORION-1 Study of AVZO-023, a Selective CDK4 Inhibitor, at the 2026 San Antonio Breast Cancer Symposium




Avenzo Therapeutics to Present Preliminary Phase 1 Results from ORION-1 Study of AVZO-023, a Selective CDK4 Inhibitor, at the 2026 San Antonio Breast Cancer Symposium

SAN DIEGO–(BUSINESS WIRE)–Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced that preliminary results from the Phase 1 portion of its ongoing Phase 1/2 ORION-1 study of AVZO-023, a selective and potentially best-in-class cyclin dependent kinase 4 (CDK4) inhibitor, will be presented as a poster at the 2026 San Antonio Breast Cancer Symposium (SABCS). The Symposium will take place December 8–11, 2026, in San Antonio, Texas.


The presentation will focus on preliminary safety, tolerability and efficacy results for AVZO-023 in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.

Poster Presentation Details

Abstract Number: 2618

Presentation Number: P1-4-13

Presentation Title: Preliminary phase 1 results from ORION-1, a phase 1/2 study of AVZO-023 with endocrine therapy and/or AVZO-021 in HR+/HER2- metastatic breast cancer (mBC)

Date/Time: Wednesday, December 9, 2026, 12:30–2:00 p.m. CT

Location: Exhibit Hall, Henry B. Gonzalez Convention Center, San Antonio, Texas

About AVZO-023

AVZO-023 is a potentially best-in-class, oral, highly potent, and selective cyclin-dependent kinase 4 (CDK4) inhibitor in development for HR+/HER2- advanced or metastatic breast cancer. It is designed to inhibit CDK4/cyclin D-mediated signaling, a central driver of tumor cell proliferation, while sparing CDK6, whose inhibition is associated with hematologic toxicity. This selectivity may support improved tolerability and combination treatment with endocrine therapy and CDK2 inhibition. AVZO-023 is being evaluated in the Phase 1/2 ORION-1 study in combination with fulvestrant or letrozole, and in a triplet combination with AVZO-021, a selective CDK2 inhibitor, and fulvestrant. Avenzo holds exclusive global rights, excluding Greater China, from Allorion Therapeutics to develop, manufacture and commercialize AVZO-023.

About AVZO-021

AVZO-021 is an oral, highly potent, and selective cyclin-dependent kinase 2 (CDK2) inhibitor in development for HR+/HER2- advanced or metastatic breast cancer and other solid tumors. It is designed to target the cyclin E/CDK2 pathway, a key mechanism of resistance to CDK4/6 inhibitors. Its high selectivity over CDK1 may limit off-target toxicity and support use in combination regimens. Enrollment is complete in the Phase 1 portion of the study evaluating AVZO-021 as monotherapy and in combination with fulvestrant. AVZO-021 is also being evaluated in the Phase 1/2 ORION-1 study in a triplet combination with AVZO-023 and fulvestrant. The triplet is intended to target both a primary driver of tumor proliferation and a key mechanism of resistance to CDK4/6 inhibitors. Avenzo holds exclusive global rights, excluding Greater China, from Allorion Therapeutics to develop, manufacture and commercialize AVZO-021.

About Avenzo Therapeutics

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company’s pipeline includes potentially differentiated small molecules and bispecific antibody-drug conjugates (ADCs). Avenzo’s small molecule inhibitors, AVZO-021 and AVZO-023, are novel, highly potent and selective inhibitors of CDK2 and CDK4, respectively, which are key enzymes involved in cell cycle regulation. AVZO-021 is being evaluated in a Phase 1/2 study as monotherapy in advanced solid tumors and in combination with fulvestrant in HR+/HER2- metastatic breast cancer. AVZO-021 and AVZO-023 are being evaluated in the Phase 1/2 ORION-1 study in HR+/HER2- metastatic breast cancer, where AVZO-023 is administered in combination with endocrine therapy, with or without AVZO-021. Avenzo’s first ADC drug candidate, AVZO-1418, is a potentially differentiated EGFR/HER3 bispecific ADC that is being studied in the AVENTINE-1 Phase 1/2 study for the treatment of advanced solid tumors. Avenzo’s second ADC drug candidate, AVZO-103, is a potentially differentiated Nectin4/TROP2 bispecific ADC that is being studied in the BEACON-1 Phase 1/2 study for the treatment of advanced solid tumors. Avenzo is headquartered in San Diego, California. For more information, visit us at www.avenzotx.com or on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: Avenzo’s expectations with respect to the presentation of data at the 2026 San Antonio Breast Cancer Symposium; the design, mechanism of action and potential benefits of AVZO-023 and AVZO-021, including with respect to selectivity, tolerability and ability to address resistance to CDK4/6 inhibitors; the timing, enrollment, design and progress of the ORION-1 study and Avenzo’s other ongoing and planned clinical trials, including the studies of AVZO-021 as monotherapy and in combination with fulvestrant, and the AVENTINE-1 and BEACON-1 studies of Avenzo’s ADC candidates AVZO-1418 and AVZO-103; the potential for Avenzo’s ADC candidates to be differentiated; Avenzo’s ability to continue to advance its potentially differentiated oncology pipeline; and other statements that are not historical facts. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: uncertainties associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials, and whether preliminary, interim or future data from such trials will support continued development or regulatory approval; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to Avenzo’s dependence on novel combination regimens that have not been validated in later-stage trials; risks related to Avenzo’s reliance on its collaborations and licenses with third parties, including Allorion Therapeutics, for the development of its product candidates; risks related to the inability of Avenzo to obtain sufficient additional capital to continue to advance its product candidates; and uncertainties regarding Avenzo’s ability to achieve its long-term goals and capitalize on opportunities. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Avenzo expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contacts

Avenzo Therapeutics
Annie Chang

Investor Relations

achang@avenzotx.com

Carla Taub

Media Relations

ctaub@avenzotx.com

Revvity Board Declares Quarterly Dividend

Revvity Board Declares Quarterly Dividend




Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.–(BUSINESS WIRE)–The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 12, 2027 to all shareholders of record at the close of business on January 22, 2027.


About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Contacts

Media Relations:
Chet Murray

(781) 462-5126

chet.murray@revvity.com

Investor Relations:
Steve Willoughby

steve.willoughby@revvity.com

Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences

Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences




Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences

FOSTER CITY, Calif.–(BUSINESS WIRE)–#GILD–Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:


  • Wolfe Research Healthcare Conference on Tuesday, November 10 at 11:20 AM Eastern Time
  • UBS Global Biopharma Conference on Tuesday, November 17 at 10:00 AM Greenwich Mean Time
  • Jefferies Global Healthcare Conference on Tuesday, November 17 at 2:30 PM Greenwich Mean Time
  • Citi’s Global Healthcare Conference on Tuesday, December 1 at 11:00 AM Eastern Time
  • Annual Evercore Healthcare Conference on Wednesday, December 2 at 11:40 AM Eastern Time

The live webcasts can be accessed on the company’s investor relations website at investors.gilead.com. The replays will be available for at least 30 days following each presentation.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Jacquie Ross, CFA – Investors
investor_relations@gilead.com